Delivering a faster, more stable, and high-yield track for your biopharmaceutical innovation journey
In today's fiercely competitive global biopharmaceutical landscape, the focus around higher yield, consistent quality, and faster time-to-market has become the universal core indicators for every drug developer. However, in the early stages, some of the common pain points include:
- Long cell line development cycles slowing down the R&D timeline.
- Low recombinant protein expression hurting batch yields and commercial cost-effectiveness.
- Poor cell line stability creating unmanageable risks for large-scale commercial production.
Altruist Biologics is proud to launch our proprietary AltruCHOice™ cell line development platform — the ultimate solution that balances speed and quality. Our mission is to accelerate the translation of your novel molecules into high-quality, commercially viable medicines faster and more efficiently.
Industry-leading high expression performance
Our proprietary AltruCHOice™ host cell line delivers industry-leading benchmark expression levels: Baseline yields easily exceed 5 g/L, with top-performing batches reaching up to 18 g/L across multiple molecular formats.
Robust stability for scalable production
Recombinant monoclonal cell pools and clonal lines maintain consistent growth, metabolism, and protein expression after over 60 continuous passages, fully meeting the rigorous requirements of large-scale commercial manufacturing.
Versatile adaptability to streamline process transfer
AltruCHOice™ cells are fully compatible with all major commercial cell culture media, and can be flexibly adapted to diverse process development workflows. This minimizes technology transfer risks and enables seamless, rapid "plug-and-play" process startup.
Significantly shortened R&D timeline
Altruist has overcome traditional R&D cycle barriers with our streamlined, efficient workflow: our platform supports single-, double-, and multi-gene expression vector construction paired with advanced, targeted gene integration technology, which drastically improves the efficiency of stable cell line generation. We can deliver a finalized PCB (RCB) from initial DNA delivery in as fast as 10 weeks, drastically cutting down project development timelines.
Full intellectual property protection and regulatory compliance
AltruCHOice™ is an independent, fully patented recombinant protein expression system developed in-house by Altruist, ensuring source-level compliance and safety for your projects. The entire workflow — from cell procurement and adaptation to master cell bank construction — is fully traceable with complete batch documentation. Combined with our transparent commercial licensing terms and comprehensive IP protection framework, we eliminate the risk of IP equity disputes during clinical application and post-marketing stages entirely.
Backed by over a decade of specialized expertise in cell line development, our mature technical system and strict compliance guarantees fully meet the regulatory requirements of global health authorities including the NMPA, FDA, and EMA. Leveraging our rich practical experience, we proactively mitigate potential development risks and maximize the success rate of your drug development projects.
We firmly believe that a strong starting point defines the final success of your journey. Choosing AltruCHOice™ means partnering to accelerate life-saving therapies to build a healthier future together.
Authors: Shuqing Chen, Ph.D., Head of Cell Line Development; Pan Lu, Senior Scientist; Teng Huang, Senior Scientist; Ye Yuan, Senior Director; Angie Yu, Director of Technical Innovation
Seamless Gene to GMP
With centralized gene-to-GMP capabilities and proven expertise, learn how Altruist provides end-to-end support for your path to market.